HealthTree Logo
search more_vert
close
person Sign In / Create Account
Patient Power: New Immunotherapies in the Myeloma Clinic
Posted: Oct 19, 2016
Patient Power: New Immunotherapies in the Myeloma Clinic image

Immunotherapies are becoming more available in myeloma clinical trials. Larry Anderson, MD, PhD of the UT Southwestern Medical Center joins Andrew Schorr on Patient Power to discuss two classes of immunotherapies that are now in clinical trials: checkpoint inhibitors and CAR T cell treatments. Dr. Anderson suggests that the checkpoint inhibitors will not be used as single therapies, but are best used with existing myeloma treatments. He also hints that checkpoint inhibitors and CAR T cell therapies may be combined at a future date.

What Are the New Game-Changing Therapies for Advanced Myeloma? from Patient Power on Vimeo. To find all clinical trials using checkpoint inhibitors, click here: Checkpoint Inhibitor Clinical Trials    

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Regeneron
Adaptive
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube